Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.
Picture of V-Bio Ventures

V-Bio Ventures

We are a life sciences fund investing throughout Europe in start-up and early-stage companies with high growth potential. Our articles cover investment-related topics in life sciences, including innovation trends, the latest business themes and exciting updates on our portfolio companies.
Icon-linkedin Link
Picture of V-Bio Ventures

V-Bio Ventures

We are a life sciences fund investing throughout Europe in start-up and early-stage companies with high growth potential. Our articles cover investment-related topics in life sciences, including innovation trends, the latest business themes and exciting updates on our portfolio companies.
Icon-linkedin Link

More good drugs than ever: a boon for society but a challenge for company coffers

In recent decades, the biotech and pharmaceutical sectors have experienced unprecedented progress, reshaping patient care through the introduction of cutting-edge therapies. A stream of novel drugs has emerged at an increasingly rapid pace, for conditions lacking approved treatments or as improved treatments where existing drugs fell short in terms of efficacy, safety, or convenience. But is the health innovation industry falling victim to its own burgeoning success?

Zapping weeds: RootWave’s herbicide-free weed control solution 

RootWave’s technology kills weeds using electricity, offering farmers an eco-friendly alternative to chemical herbicides. The eWeeding solution supports our transition towards a more sustainable agricultural industry, protecting the health of both people and the planet.

The rise and recalibration of sustainable agrifood investments: lessons for us all

There has been an unprecedented surge of investments in sustainable agriculture and food technologies in the last decade, but that trend now appears to have reversed into a free fall in funding. This pattern of promise-to-disillusionment perfectly matches the hype cycle previously demonstrated by breakthrough technologies in other sectors. Can we forge a path forward for sustainable agrifood start-ups?

Mutually beneficial success: the importance of the founder-VC partnership

The adage ‘teamwork makes the dream work’ rings especially true in the dynamic realm of biotech startups. Most successful biotech companies have a foundation built on a robust relationship between their founders and venture capital (VC) partners. This founder-VC partnership represents a symbiotic relationship between a venture capital firm and the founding team of a biotech startup. But what are the key factors for a successful partnership?

V-Bio Ventures leads €20 million Series A financing of Precision oncology company Flindr Therapeutics to advance first-in-class small molecule inhibitors

Will the looming pharma patent cliff start driving a super cycle of biotech deals?

After several years of dismal market activity, 2024 is already looking up for deals in the pharmaceutical industry, with a recent flurry of billion-dollar mergers and acquisitions. Is this trend being driven by the impending loss of revenue caused by soon-to-expire blockbuster drug patents? And what does it mean for earlier-stage biotech startups?

Fraud in scientific institutes: a crack in the fabric of science

The pursuit of scientific knowledge is at the heart of human progress – it leads to ground-breaking discoveries that have transformed our understanding of the world and our place within it. However, this noble pursuit is not without its blemishes. Scientific fraud – the deliberate misrepresentation of data or results to deceive the scientific community – poses a serious threat to the integrity of the scientific enterprise in both academia and industry. So, what can we do about it?

Bridging the immunity gap: improving animal welfare without antibiotics

Antibiotic resistance is a major concern for humans and animals. Increasing pressure to move away from antibiotics has created space for new solutions for disease management. Animab’s oral monoclonal antibody platform is a promising alternative, effectively guarding against infection during a vulnerable period in an animal’s development.

V-Bio Ventures portfolio company Protealis secures EUR 22 million in oversubscribed B round funding to propel sustainable plant protein seed solutions

Protealis, a leading innovator in seed solutions for sustainable plant proteins based in Ghent, Belgium, proudly announced today the successful completion of its B-Round funding, raising a substantial EUR 22 million.

How the Chair of the Board can empower a first-time biotech CEO

Stepping into the role of a Chief Executive Officer (CEO) for the first time can be a daunting prospect. In the biotech industry, the journey is marked by a unique set of hurdles, from scientific complexities, to regulatory intricacies, finance, HR, and interactions with a wide range of stakeholders. In this dynamic landscape, the role of the Chair of the Board of Directors becomes pivotal. The Chair is well-positioned to empower and support first-time CEOs, but good synergy between the duo is paramount for success.

V-Bio Ventures-funded Tanai Therapeutics develops first-in-class therapeutics for obesity

VIB, Flanders’ leading life sciences institute, together with lead investor V-Bio Ventures has launched a new spin-off company based on research at the VIB-UGent Center for Inflammation Research. With an initial seed financing round supported by V-Bio Ventures, Qbic and VIB, the spin-off company is entering the obesity space with an entirely novel therapeutic approach.

The rise of women’s health

It’s been a Barbie world this summer with crowds of pink-clad moviegoers flooding the cinemas. Simultaneously, we’ve been witnessing a rush of ‘pink’ fundraising for women’s health start-ups. From pre-clinical to clinical: more companies are entering the field and developing solutions for women’s unique needs. But is their focus broad and innovative enough? And are pharma companies paying attention?

Muna Therapeutics: hopeful solutions for memory loss

Muna Therapeutics is developing transformative therapies for neurodegenerative diseases. These drugs aim to preserve cognition and enhance the brain’s resilience in diseases like Alzheimer’s and Parkinson’s, providing much-needed hope for millions of patients and their loved ones.

V-Bio Ventures portfolio company Agomab raises $100 million Series C to advance fibrosis-focused pipeline

Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.

Lean years for company creation in Europe?

After an exceptional sequence of socio-economic shocks over the past few years, the number of new companies being formed in key European biotech hubs has stalled. Early-stage investors need to roll up their sleeves and help to crank the engine of EU innovation back to life.